USFDA grants Orphan Drug Designation (ODD) to Zydus’ Desidustat for treatment of beta-thalassemia EP News Bureau Nov 6, 2025 Zydus, a leading, discovery-based, global pharmaceutical company announced that the USFDA has granted Orphan Drug Designation…
US FDA approves Casgevy, cell-based gene therapy to treat transfusion-dependent beta-thalassemia EP News Bureau Jan 18, 2024 The approval signifies a second FDA-approved indication for Casgevy, as the product was also recently approved for the treatment…
